An Emergent Company
Caisson’s patented HEPtune® technology improves the half-life of peptides, proteins, and small molecule drugs.
Caisson applies HEPtune® linker technology to enhanced antibody drug conjugates (ADCs).
Caisson’s HEPtune® technology engineered to improve the delivery of liposomes.